MedTrace Logo

Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma

NCT04850846 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-02-09

Study results available
· View outcomes & findings →

Summary

The purpose of this research is to understand whether the drug metformin could be used in the future to help prevent patients with monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) from developing multiple myeloma.

The names of the study drug involved in this study is:

* Metformin, extended release
* Placebo ( a pill that has no active ingredients)

Conditions

  • Monoclonal Gammopathy of Undetermined Significance
  • Smoldering Multiple Myeloma

Interventions

DRUG

Metformin XR

Orally by mouth

OTHER

Placebo

Orally by mouth

Sponsors & Collaborators

Principal Investigators

  • Omar Nadeem, MD · Dana-Farber Cancer Institute

  • Catherine R Marinac, PhD · Dana-Farber Cancer Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-27
Primary Completion
2025-01-29
Completion
2027-07-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04850846 on ClinicalTrials.gov